Provider Action — Key Authorization & Documentation Notes

Prior authorization requirements and documentation vary by product. Many biologic and targeted therapies include an explicit requirement that there be no concurrent use with another systemic biologic or targeted small molecule for the same indication. For products where documentation, step therapy, or explicit authorization/denial rules are not specified in the source chunks, no additional authorization steps or documentation instructions are provided in this section — reviewers should presume standard prior authorization submission (diagnosis, relevant labs/imaging, prior therapy history) unless product-specific requirements are listed elsewhere in the policy.

• No concurrent systemic biologic/targeted small molecule: Several products (e.g., ORENCIA, multiple psoriasis/autoimmune biologics, asthma biologics, and others listed) include an explicit prohibition on concurrent use with another systemic biologic or targeted small molecule (e.g., JAK inhibitors, PDE-4 inhibitors) for the same indication.
• Missing / not specified items: Many chunks do not include explicit authorization or denial triggers, documentation instructions, or step therapy rules; where the source is silent, there are no additional provider-action steps described in this section.
• Product identifiers and packaging detail: For syringe/insulin injection supplies and related items, detailed product identifiers and packaging/SKU information are listed (pen needles, syringe sizes, needle gauges).

Documentation — When to Include Supporting Evidence

Where product-specific documentation requirements are listed in the policy (for example: mutational analysis for Scemblix; genetic/biochemical confirmation for Strensiq; baseline vitals for droxidopa; culture results for ARIKAYCE; diagnostic confirmation for carglumic acid; prior CDI antibiotic treatment and failure criteria for VOWST), those requirements must be submitted with the PA request. If a product entry does not list documentation instructions or authorization/denial criteria, no additional documentation requirements are specified here.

• Submit product-specific supporting documentation when explicitly required by the product entry (labs, genetic tests, imaging, specialist consultation notes, prior treatment trials).
• If renewal criteria are listed (e.g., continues to benefit, negative cultures, improvement in disease markers), include evidence to support continued benefit.
• No explicit denial triggers listed: Several chunks do not contain explicit denial triggers; absence of a listed denial condition does not remove the need to meet any stated inclusion/exclusion criteria.

Step Therapy / Prior Trials

Step therapy and prior trial requirements are specified only for products where noted (examples include conventional synthetic DMARD trials for RA, trials of oral immunosuppressants or phototherapy for psoriasis, prior antiemetic for dronabinol, prior AEDs for Fintepla, trial of JAKAFI for Inrebic, etc.). For many products and syringe/insulin supply listings, no step therapy rules are provided in these chunks.

• When step therapy is required, document prior agents tried, dates, doses, and reason for discontinuation (failure, intolerance, or contraindication).
• If the chunk contains no step therapy requirement, none is specified in this section for that product.

Denial Risk — What Triggers Potential Denial

Denial risk arises if required product-specific criteria are not met (e.g., lack of required genetic testing, absence of specialist consultation when required, concurrent use of disallowed therapies, or failure to show continued benefit at renewal). However, many chunks do not list explicit denial triggers; reviewers should apply the listed inclusion/exclusion and "no concurrent use" rules and request missing documentation before denial where appropriate.

• Denial may be appropriate when the product-specific inclusion/exclusion criteria are not satisfied (e.g., missing diagnostic confirmation, required lab thresholds not met, or prohibited concurrent therapy present).
• When the policy chunk is silent on denial triggers, there is no additional explicit denial rule in this section beyond meeting the stated criteria.